Allogenic cardiac stem cells administration for the treatment of acute Myocardial Infarction

What is it about?

Most studies use autologous cardiac stem cells (CSCs), with the timing constraints this imposes. The use of allogeneic CSCs would allow for early administration. We undertook this study to assess the safety of early delivery and the possible influence of the timing of allogeneic porcine CSCs (pCSCs) delivery after acute myocardial infarction (AMI) on cardiac function.

Featured Image

Why is it important?

Injection of pCSCs was successful in all animals at both 0 and 7 days after AMI, in absence of major adverse cardiac events. No significant differences in MR-derived cardiac function parameters or infarct sizes were seen in any case, but a trend towards better function and limited chamber dilatation at 10 weeks was seen in the treated groups.